CAPTRUST Financial Advisors
CPRX

CAPTRUST Financial Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$896K Buy
36,190
+1,630
+5% +$38.8K ﹤0.01% 1677
2025
Q4 		$807K Buy
34,560
+14,926
+76% +$332K ﹤0.01% 1622
2025
Q3 		$387K Sell
19,634
-2,114
-10% -$43.5K ﹤0.01% 1996
2025
Q2 		$472K Buy
+21,748
New +$513K ﹤0.01% 1766
2022
Q3 		– Sell
-599
Closed -$4K – 2461
2022
Q2 		$4K Buy
599
+304
+103% +$2.23K ﹤0.01% 4169
2022
Q1 		$2K Sell
295
-1,170
-80% -$8.27K ﹤0.01% 4467
2021
Q4 		$10K Sell
1,465
-651
-31% -$4.28K ﹤0.01% 3700
2021
Q3 		$11K Sell
2,116
-113
-5% -$618 ﹤0.01% 3537
2021
Q2 		$13K Buy
2,229
+113
+5% +$583 ﹤0.01% 3372
2021
Q1 		$10K Buy
2,116
+1,989
+1,566% +$7.9K ﹤0.01% 3422
2020
Q4 		$0 Hold
127
– – ﹤0.01% 3416
2020
Q3 		$0 Buy
+127
New +$497 ﹤0.01% 3077

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

CAPTRUST Financial Advisors's CPRX Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 4.7% in Q1 2026, buying an estimated $38.8K and bringing the position to 36,190 shares worth $896K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

CAPTRUST Financial Advisors first reported a position in CPRX in Q3 2020 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • CAPTRUST Financial Advisors held 36,190 shares of Catalyst Pharmaceutical worth $896K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 1,630 Catalyst Pharmaceutical shares in Q1 2026, an estimated $38.8K.
  • Catalyst Pharmaceutical made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1677 holding.
  • CAPTRUST Financial Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 12 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.